BMET-37 PHASE I STUDY OF AZD3759, AN EGFR INHIBITOR WITH BLOOD BRAIN BARRIER (BBB) PENETRATION, FOR THE TREATMENT OF EGFRm+ NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASIS AND LEPTOMENGINGEAL METASTASIS

Lignende værker

• BMET-10 VASCULOGENIC MIMICRY IN LUNG CANCER BRAIN METASTASIS
  af: Chen, Zhongping
  Udgivet: (2015)
• BMET-35 CERITINIB IN ALK+ NSCLC METASTATIC TO BRAIN AND/OR LEPTOMENINGES: THE ASCEND-7 STUDY
  af: Wen, Patrick Yung, et al.
  Udgivet: (2015)
• BMET-36 TUMOR PROFILES OF BRAIN METASTASES FROM NSCLC, BREAST CANCER AND MELANOMA
  af: Kesari, Santosh, et al.
  Udgivet: (2015)
• BMET-38 METASTASIS TO BRAIN AND LUNG IN CARCINOSARCOMA OF THE PAROTID GLAND - A CASE REPORT
  af: Yang, Seung Ho, et al.
  Udgivet: (2015)
• BMET-19 CLINICOPATHOLOGICAL SIGNIFICANCE OF N-CADHERIN AND VEGF IN ADVANCED GASTRIC CANCER BRAIN METASTASIS AND THE EFFECTS OF METFORMIN IN PRECLINICAL MODELS
  af: Kim, Young Il, et al.
  Udgivet: (2015)